Department of Urology, National Defense Medical College, Saitama, Japan.
Department of Diagnostic Pathology, Keio University School of Medicine, Tokyo, Japan.
Jpn J Clin Oncol. 2020 Oct 22;50(11):1313-1320. doi: 10.1093/jjco/hyaa114.
In our multicenter study evaluating metastatic papillary renal cell carcinoma (PRCC), 29% of tumors diagnosed as PRCC in collaborative institutes were finally diagnosed as other RCCs under central review. In those tumors, mucinous tubular and spindle cell carcinoma (MTSCC) was the leading histology, followed by unclassified RCC (ucRCC). We focused on those patients with MTSCC or ucRCC.
We reviewed the processes for the pathological diagnoses of nine tumors and reviewed their clinical features.
All of the MTSCCs and ucRCCs were positive for AMACR, which is frequently positive in PRCC. Mucin was demonstrated in 80% of the MTSCCs, and its presence is important for their diagnoses. One MTSCC was diagnosed as a mucin-poor variant. The presence of spindle cells with low-grade nuclei was suggestive of MTSCC, but the diagnosis of high-grade MTSCC was difficult. Four tumors were diagnosed as ucRCC by histological and immunohistochemical findings. Three of the four tumors were suspicious of ucRCC in the initial review due to atypical findings as PRCC. Sunitinib and interferon-α were effective for one MTSCC patient who survived for >5 years. Two MTSCC patients who were Memorial Sloan-Kettering Cancer Center poor risk had unfavorable prognoses. One patient with mucin-poor MTSCC had an indolent clinical course. Two of four ucRCC patients showed durable stable disease with targeted agents (TAs) and survived >3 years.
Some MTSCC metastases progressed very slowly and poor-risk tumors progressed rapidly. Systemic therapies including TAs showed some efficacies. Some patients who have metastatic ucRCC with microscopic papillary architecture can benefit from TAs.
在我们的多中心研究中,评估转移性乳头状肾细胞癌(PRCC),在协作机构诊断为 PRCC 的肿瘤中有 29%在中心审查下最终被诊断为其他 RCC。在这些肿瘤中,黏液管状和梭形细胞癌(MTSCC)是主要组织学类型,其次是非分类 RCC(ucRCC)。我们重点关注那些患有 MTSCC 或 ucRCC 的患者。
我们回顾了 9 例肿瘤的病理诊断过程,并回顾了其临床特征。
所有 MTSCC 和 ucRCC 均为 AMACR 阳性,这在 PRCC 中经常阳性。80%的 MTSCC 中存在黏液,其存在对诊断很重要。1 例 MTSCC 被诊断为黏液缺乏型。存在低级别核的梭形细胞提示为 MTSCC,但高级别 MTSCC 的诊断困难。4 例肿瘤通过组织学和免疫组织化学发现被诊断为 ucRCC。由于与 PRCC 相似的非典型表现,在最初的审查中,其中 3 例被怀疑为 ucRCC。1 例 MTSCC 患者接受舒尼替尼和干扰素-α治疗,生存时间超过 5 年。2 例 MTSCC 患者被 Memorial Sloan-Kettering Cancer Center 评为高危,预后不良。1 例黏液缺乏型 MTSCC 患者具有惰性临床病程。4 例 ucRCC 患者中的 2 例接受靶向药物(TAs)治疗后疾病稳定持续超过 3 年。
一些 MTSCC 转移进展非常缓慢,高危肿瘤进展迅速。包括 TAs 在内的全身治疗显示出一定的疗效。一些具有显微镜下乳头状结构的转移性 ucRCC 患者可以从 TAs 中获益。